Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK-92/5.28.z Cells With or Without Ezabenlimab in Recurrent HER2-positive Glioblastoma
NCT03383978Phase 1Recruiting
- Sponsor
- Universitätsklinikum Frankfurt
- Start
- Dec 2017
- Primary completion
- Dec 2027
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NK-92/5.28.z cells in glioblastoma (GBM) and Gliosarcoma (GS), sponsored by Universitätsklinikum Frankfurt. Primary endpoints: Treatment-Related Adverse Events at 24 weeks, Maximum Tolerated Dose at 24 weeks and 2 more. Started Dec 2017; status: recruiting.
02
Drugs
NK-92/5.28.z cells
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT03383978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03383978.